

Registered number: 06981121  
Charity number: 1132271

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

**UNAUDITED**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 MARCH 2016**



---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
**(A company limited by guarantee)**

---

---

**CONTENTS**

---

	Page
<b>Reference and administrative details of the charity, its trustees and advisers</b>	1
<b>Trustees' report</b>	2 - 6
<b>Independent examiner's report</b>	7
<b>Statement of financial activities</b>	8
<b>Balance sheet</b>	9
<b>Notes to the financial statements</b>	10 - 21

---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
**(A company limited by guarantee)**

---

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS  
FOR THE YEAR ENDED 31 MARCH 2016**

---

**Trustees**

Jayesh Pindolia  
Patrick Phillips (resigned 6 June 2015)  
Michael Porter, Chairman  
Wendy Bascal (resigned 25 November 2015)  
Shaun Griffin  
Stuart Alderson

**Company registered number**

06981121

**Charity registered number**

1132271

**Registered office**

Black Country House, Rounds Green Road, Oldbury, West Midlands, B69 2DG

**Independent examiner**

Helen Drew FCA, Black Country House, Rounds Green Road, Oldbury, West Midlands, B69 2DG

---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

---

**TRUSTEES' REPORT  
FOR THE YEAR ENDED 31 MARCH 2016**

---

The Trustees present their annual report together with the financial statements of for the 1 April 2015 to 31 March 2016.

Since the company qualifies as small under section 383, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

**Objectives and Activities**

**a. POLICIES AND OBJECTIVES**

The objects of the Association for Glycogen Storage Disease (UK) as recorded in its Memorandum of Association, is "The relief of sickness, particularly of persons suffering from any form of Glycogen Storage Disease". The Association works to protect and promote the best interests of persons affected by GSD.

**PUBLIC BENEFIT**

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to public benefit guidance published by the Commission in determining the activities undertaken by the Charity.

The Charity Commission in its "Charities and Public Benefit" Guidance states that there are two key principles to be met in order to show that an organisation's aims are for the public benefit: firstly, there must be an identifiable benefit and secondly, that benefit must be to the public or a section of the public. The Trustees are satisfied that the aims and objectives of the charity, and the activities reported on below to achieve those aims, meet these principles.

**b. STRATEGIES FOR ACHIEVING OBJECTIVES**

The Association acts as a vehicle of communication on GSD related matters by publishing and distributing relevant material. It contributes to the advancement of treatments and cures through sponsorship of research, studies and trials. It acts as a focus for educational, scientific and charitable activities related to GSD. The Association liaises with other GSD Associations around the world.

**c. ACTIVITIES FOR ACHIEVING OBJECTIVES**

The main activities are the support of patients and families; the organising of conferences and workshops to promote understanding of the disease; the publication of a newsletter; the provision of information about Glycogen Storage Disease through publications and a web site; and the provision of grants to research bodies and individuals. These activities support the objects by assisting patients; by encouraging and supporting research into the disease and by educating the medical profession and concerned members of the general public about the disease.

**d. GRANT MAKING POLICIES**

The Association receives applications for grants to support research projects in relation to Glycogen Storage Disease. Applications for grants are considered by the Board of Trustees and by members of the Association's Medical Advisory Board. Whenever possible the Association co-sponsor together with other charities or foundations. The Association also occasionally makes small grants to individual applicants for personal expenses associated with their treatment, care and well-being.

---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

---

**TRUSTEES' REPORT (continued)**  
**FOR THE YEAR ENDED 31 MARCH 2016**

---

**Achievements and performance**

**a. REVIEW OF ACTIVITIES**

The reporting year was extremely busy and rewarding for the AGSD-UK. Although the staffing levels remained low in order to control costs, the Charity Director, Trustees and volunteer staff were engaged and active.

During the year due to work and family commitments two long serving trustees resigned from the trustee board. This leaves the charity with four trustees and the board recognise the need to recruit at least two more trustees, they are keen to increase the board representation of patient groups and also have an increased gender mix.

In December funding was secured to recruit a member of staff to support patients and families living with Pompe Disease. This post replaced the Family Support Officer, based at Manchester Children's Hospital and was funded through the NHS on behalf of the charity. Funding for that role ceased on 31st December 2015. Following a recruitment and selection process the Specialist Care Advisor began work in late March during the final week of the AGSD-UK financial year.

Throughout the year the Chairman and Charity Director arranged a number of local meetings with the AGSD-UK Medical Advisory Board to discuss the charity objectives and the specialist metabolic service provided to our members. This was found to be a more practical arrangement than trying to gather all advisory board members together in one place at the same time.

In October the annual conference was held at Wyboston Lakes Training Centre, Bedfordshire. It was very well attended by 150 delegates, the largest turnout for some years and was again designed with fewer scientific presentations in order to provide more opportunities for discussion. Feedback from attendees was largely excellent.

Grant applications were disappointing once again this year. Applications to the Big Lottery Fund and GSK Impact Awards were unsuccessful, although it is hoped to use the experience and feedback to improve future submissions. For that reason a small grant has been approved to cover the costs of a fundraising consultant for one day per week over three months during the next financial year with the aim of developing a pipeline of submissions and a library of grant collateral.

The GSD Giant cycling event was cancelled this year due to low registration numbers. It was replaced however with a short cycle ride that was well attended raising valuable funds for the charity.

Two fundraising supporters took part in a London to Paris bike ride organised by Classic Tours. The charity would ideally like to attract many more participants in group activities such as this; a Moroccan Trek was cancelled as it failed to attract any willing participants.

After focus group meetings and discussions with volunteers and members it was decided to launch a new campaign to encourage members and supporters to raise funds for the charity. The "Bake or Burn" campaign has a slogan: "making calories count" and a logo designed professionally. It is aimed at providing all AGSD-UK members and supporters with a focus to plan events with either physical challenges or activities more suited to people with GSD conditions causing exercise intolerance (cake sales, tea parties, etc.).

During the year meetings were held with the GSD Type coordinators for them to exchange ideas, learn from each other and help to plan fundraising events and the annual conference. The charity has recruited a coordinator for GSD type 0 for the first time in its history.

The AGSD-UK extended its published literature to include a leaflet explaining GSD VI. Leaflets such as this are vital for conditions that are so rare that most primary care centres will have no experience of them.

The newly formed Pompe Support Team having received a grant from Amicus Therapeutics to develop a book full of advice for late-onset Pompe disease, "101 Tips for an easier life with Pompe Disease" has made good

---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
**(A company limited by guarantee)**

---

**TRUSTEES' REPORT (continued)**  
**FOR THE YEAR ENDED 31 MARCH 2016**

---

progress and it is expected to be published around mid 2016.

A meeting was held in London with parents of children with Pompe disease. The purpose was to understand their feelings towards Gene Therapies that are being developed to alleviate the respiratory and neuromuscular problems in such children.

International Pompe Day was again celebrated in April. The Pompe Support Team arranged a social event at the Hilton, Coventry. The Saturday was well attended and was very much appreciated by those present.

The McArdle Advisory Panel continued to meet with the NHS Highly Specialised Service for McArdle Disease at the National Hospital for Neurology and Neurosurgery.

The McArdle walking courses were once again well attended. These are run in Wales by our GSD Type V coordinator and are designed to demonstrate to those with McArdle Disease how to exercise effectively and safely and help patients achieve far more than they had previously thought possible. For the first time a course was also run for children with the condition, and their parents. Feedback from the courses was excellent and they are endorsed by the medical team at the McArdle Clinic in London.

AGSD-UK continues to provide a patient group input to the Euromac Registry consortium by undertaking the "Dissemination" work package. This work is funded by the EU over three years and helps to defray some of the charity's staff and overhead costs.

The trustee board continued to make progress on developing the requirements for replacing the current AGSD-UK website with a more modern and up-to-date one. Outline requirements have been agreed and a supplier evaluation and selection exercise has been undertaken. Once funding has been secured the charity will be in a position to initiate a quick start to the project. Contained within the scope of the project and underpinning the new website will be the implementation of a more robust and secure IT infrastructure. In parallel a comprehensive set of policies and procedures are being developed and while this level of surety is not currently required for a charity the size of AGSD-UK the trustees believe it will substantially improve the chances of becoming more successful in our large grant submissions.

The charity is extremely grateful for the continuing support of our donors, fund raisers, grant makers and various sponsors from Pharmaceutical, Nutrition, and Biotechnology industries. Their efforts on behalf of the charity enables it to maintain its support to all people affected by GSD in the UK.

---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

---

**TRUSTEES' REPORT (continued)**  
**FOR THE YEAR ENDED 31 MARCH 2016**

---

**Financial review**

**a. GOING CONCERN**

The company has cash resources and has no requirement for external funding. Actions taken have cut the deficit and increased income post balance sheet, such that at the date of signing the accounts the unrestricted reserves stand at £12,766. The trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting is appropriate in preparing the annual financial statements.

**b. INVESTMENT POLICY AND PERFORMANCE**

The Association holds its cash reserves in bank deposit accounts thus eliminating investment risk and minimising any other risk to the reserves. No long-term deposits are made as it is anticipated that the reserves will continue to be called upon to support a high level of activity.

**c. RESERVES POLICY**

The Association holds some funds that are restricted in expenditure in support of particular GSD Types and other projects (see note 17). The general reserves are used to support the on-going activities of the Association. The unrestricted general reserve now stands at £12,766 which is a substantial increase from the previous year (£1,699) and reflects the trustees focus on increasing income while tightly managing costs.

In line with most small charities AGSD-UK aims to spend most of the funds raised during any given financial year for the benefit of its members and the public and not to build up a large general reserve. The trustees have agreed to adopt a reserve policy that seeks to carry forward an unrestricted general reserve figure that is no greater than 25% of total in-year expenditure.

**Structure, governance and management**

**a. CONSTITUTION**

The company is registered as a charitable company limited by guarantee and was set up a Memorandum of Association.

The company is constituted under a Memorandum of Association dated 05/08/2009 and is a registered charity number 1132271.

The principal object of the company is to provide "The relief of sickness, particularly of persons suffering from any form of Glycogen Storage Disease".

**b. METHOD OF APPOINTMENT OR ELECTION OF TRUSTEES**

The management of the company is the responsibility of the Trustees who are elected and/or co-opted under the terms of the Articles of Association. Any full member of the Association may be nominated to stand for election to the Board of Trustees. The Trustees have the power to co-opt new Trustees who are then required to stand for election at the next AGM.

**c. REMUNERATION OF KEY MANAGEMENT PERSONNEL**

The company currently has two part time permanent members of staff – Charity Director and Specialist Care Advisor. The remuneration for both posts was benchmarked at or below market rate prior to appointment and is reviewed by Trustees annually.

---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
**(A company limited by guarantee)**

---

**TRUSTEES' REPORT (continued)**  
**FOR THE YEAR ENDED 31 MARCH 2016**

---

**d. ORGANISATIONAL STRUCTURE AND DECISION MAKING**

The Association is a membership based association, with full membership being open to anyone affected by Glycogen Storage Disease and the close family of such persons. The members elect the Board of Trustees. The Board of Trustees elects its own officers. The Board of Trustees are responsible for ensuring that the charity complies with all relevant regulations and files its annual report and accounts with the Charity Commission and Companies House.

The Board of Trustees delivers the strategy through the Development Director and any other staff plus a range of volunteers.

The Board appoint a volunteer Co-ordinator for each of the GSD Types, wherever possible. The defined role is wide ranging and is not necessarily entirely relevant or practical for each GSD Type, where the numbers affected and their needs vary enormously. The Co-ordinators are supported by the Development Director. They meet as a group three times a year for peer support and development in their role.

**e. RISK MANAGEMENT**

The Trustees have assessed the major risks to which the company is exposed. The current major risks to the charity are primarily in the areas of operation and finance as follows:

- Income generation
- Cost control
- Banking control
- I.T. stability and security
- Adoption of and adherence to policies and procedures
- Loss of key personnel

The Trustees are satisfied that systems, procedures and plans are in place to mitigate exposure to major risks.

**Plans for future periods**

**a. FUTURE DEVELOPMENTS**

The overall activity of the Association is guided by charitable objectives and the detail is provided in a Strategic Plan.

This report was approved by the Trustees on 14/11/16 and signed on their behalf by:



**Michael Porter, Chairman**  
Trustee



---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

---

**INDEPENDENT EXAMINER'S REPORT  
FOR THE YEAR ENDED 31 MARCH 2016**

---

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**

I report on the financial statements of the company for the year ended 31 March 2016 which are set out on pages 8 to 21.

This report is made solely to the company's Trustees, as a body, in accordance with section 145 of the Charities Act 2011 and regulations made under section 154 of that Act. My work has been undertaken so that I might state to the company's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the company and the company's Trustees as a body, for my work or for this report.

**RESPECTIVE RESPONSIBILITIES OF TRUSTEES AND EXAMINER**

The Trustees, who are also the directors of the company for the purposes of company law, are responsible for the preparation of the financial statements. The Trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the Act) and that an independent examination is needed.

Having satisfied myself that the company is not subject to audit under charity or company law and is eligible for independent examination, it is my responsibility to:

- examine the financial statements under section 145 of the Act;
- follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the Act; and
- state whether particular matters have come to my attention.

**BASIS OF INDEPENDENT EXAMINER'S REPORT**

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you as Trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the financial statements present a 'true and fair view' and the report is limited to those matters set out in the statement below.

**INDEPENDENT EXAMINER'S STATEMENT**

In connection with my examination, no matter has come to my attention:

- (1) which gives me reasonable cause to believe that in any material respect the requirements:
  - to keep accounting records in accordance with section 386 of the Companies Act 2006; and
  - to prepare financial statements which accord with the accounting records and comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities have not been met; or
- (2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the financial statements to be reached.

Signed:

Helen Drew

FCA

Dated:

16-11-16

Crowe Clark Whitehill LLP  
Black Country House  
Rounds Green Road  
Oldbury  
B69 2DG

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE ACCOUNT  
FOR THE YEAR ENDED 31 MARCH 2016**

	Note	Restricted funds 2016 £	Unrestricted funds 2016 £	Total funds 2016 £	Total funds 2015 £
<b>INCOME FROM:</b>					
Donations and grants	2	51,226	26,350	77,576	64,806
Other trading activities	3,4	44,094	15,389	59,483	63,447
Investments	5	-	120	120	53
<b>TOTAL INCOME</b>		<b>95,320</b>	<b>41,859</b>	<b>137,179</b>	<b>128,306</b>
<b>EXPENDITURE ON:</b>					
Raising funds	4,6	7,060	3,791	10,851	19,092
Charitable activities		78,757	27,001	105,758	94,235
<b>TOTAL EXPENDITURE</b>	10	<b>85,817</b>	<b>30,792</b>	<b>116,609</b>	<b>113,327</b>
<b>NET INCOME AND MOVEMENT IN FUNDS</b>		<b>9,503</b>	<b>11,067</b>	<b>20,570</b>	<b>14,979</b>
<b>RECONCILIATION OF FUNDS:</b>					
Total funds brought forward		76,060	1,699	77,759	62,780
<b>TOTAL FUNDS CARRIED FORWARD</b>		<b>85,563</b>	<b>12,766</b>	<b>98,329</b>	<b>77,759</b>

All activities relate to continuing operations.

The notes on pages 10 to 21 form part of these financial statements.

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
**(A company limited by guarantee)**  
**REGISTERED NUMBER: 06981121**

**BALANCE SHEET**  
**AS AT 31 MARCH 2016**

	Note	2016 £	2015 £
<b>FIXED ASSETS</b>			
Tangible assets	13	721	809
<b>CURRENT ASSETS</b>			
Debtors	14	16,701	5,512
Cash at bank and in hand		88,338	78,653
		<u>105,039</u>	<u>84,165</u>
<b>CREDITORS:</b> amounts falling due within one year	15	<u>(7,431)</u>	<u>(7,215)</u>
<b>NET CURRENT ASSETS</b>		<u>97,608</u>	<u>76,950</u>
<b>NET ASSETS</b>		<u>98,329</u>	<u>77,759</u>
<b>CHARITY FUNDS</b>			
Restricted funds	17	85,563	76,060
Unrestricted funds	17	12,766	1,699
<b>TOTAL FUNDS</b>		<u>98,329</u>	<u>77,759</u>

The Trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act.

The Trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements which give a true and fair view of the state of affairs of the company at 31 March 2016 and of its net incoming resources for the year in accordance with the requirements of sections 394 and 395 of the Act and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements were approved by the Trustees on 14/11/2016 and signed on their behalf, by:

  
**Michael Porter, Chairman**

The notes on pages 10 to 21 form part of these financial statements.

---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2016**

---

**1. ACCOUNTING POLICIES**

**1.1 Company status**

The Association for Glycogen Storage Disease (UK) Limited is a company limited by guarantee in England, whose registered office is Black Country House, Rounds Green Road, Oldbury, West Midlands, B29 2DG. The company's registered number is 06981121. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

**1.2 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006

Association for Glycogen Storage Disease (UK) Limited meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

**1.3 Reconciliation with previous Generally Accepted Accounting Practice**

In preparing these accounts, the Trustees have considered whether in applying the accounting policies required by FRS 102 and the Charities SORP FRS 102 the restatement of comparative items was required.

No restatements were required.

**1.4 Going concern**

The company has cash resources and has no requirement for external funding. Actions taken have cut the deficit and increased income post balance sheet, such that at the date of signing the accounts the unrestricted reserves stand at £12,766. The trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

**1.5 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2016**

---

**1. ACCOUNTING POLICIES (continued)**

**1.6 Income**

All income is recognised once the company has entitlement to the income, certainty of receipt and the amount can be measured with sufficient reliability.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**1.7 Expenditure**

Expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating voluntary income are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

**1.8 Cash flow**

The company has taken advantage of the exemption in Financial Reporting Standard No.1 from the requirement to produce a cash flow statement on the grounds that it is a small charitable company.

**1.9 Tangible fixed assets and depreciation**

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Office equipment	-	25% Reducing balance
------------------	---	----------------------

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2016**

**1. ACCOUNTING POLICIES (continued)**

**1.10 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

**1.11 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount repaid net of any trade discounts due.

**1.12 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

**1.13 Financial instruments**

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently at their settlement value at the balance sheet date.

**1.14 Significant accounting estimates and areas of judgement**

Preparation of the financial statements may require management to make significant judgments and estimates. There are no significant judgements or estimates having a material effect on the financial statements.

**2. INCOME FROM DONATIONS AND LEGACIES**

	<b>Restricted funds 2016 £</b>	<b>Unrestricted funds 2016 £</b>	<b>Total funds 2016 £</b>	<b>Total funds 2015 £</b>
Donations	246	9,297	9,543	35,847
Legacies	123	82	205	-
Grants	50,857	14,652	65,509	26,494
Gift aid	-	2,319	2,319	2,465
	<hr/>	<hr/>	<hr/>	<hr/>
Total donations and legacies	<b>51,226</b>	<b>26,350</b>	<b>77,576</b>	<b>64,806</b>

In 2015, of the total income from donations and legacies, £23,466 was to unrestricted funds and £41,340 was to restricted funds

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2016**

**3. ACTIVITIES TO GENERATE FUNDS**

	<b>Restricted funds 2016 £</b>	<b>Unrestricted funds 2016 £</b>	<b>Total funds 2016 £</b>	<b>Total funds 2015 £</b>
Fundraising	23	9,460	9,483	3,481
Fundraising - GSD Giant	-	5,164	5,164	15,050
	<u>23</u>	<u>14,624</u>	<u>14,647</u>	<u>18,531</u>

In 2015, of the total fundraising income, £18,012 was to unrestricted funds and £ 519 was to restricted funds.

**4. INCOMING RESOURCES FROM CHARITABLE ACTIVITIES**

	<b>Restricted funds 2016 £</b>	<b>Unrestricted funds 2016 £</b>	<b>Total funds 2016 £</b>	<b>Total funds 2015 £</b>
Conference	38,217	-	38,217	39,631
Subscriptions	-	765	765	785
Book sales	399	-	399	1,873
Walking courses	5,455	-	5,455	2,627
	<u>44,071</u>	<u>765</u>	<u>44,836</u>	<u>44,916</u>
Incoming resources from charitable activities	<u>44,071</u>	<u>765</u>	<u>44,836</u>	<u>44,916</u>

In 2015, of the total income from charitable activities, £20,416 was to unrestricted funds and £24,500 was to restricted funds.

**5. INVESTMENT INCOME**

	<b>Restricted funds 2016 £</b>	<b>Unrestricted funds 2016 £</b>	<b>Total funds 2016 £</b>	<b>Total funds 2015 £</b>
Investment income	-	120	120	53

In 2015, of the total investment income, £ 53 was to unrestricted funds and £ NIL was to restricted funds.

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2016**

**6. FUNDRAISING TRADING**

	<b>Restricted funds 2016 £</b>	<b>Unrestricted funds 2016 £</b>	<b>Total funds 2016 £</b>	<b>Total funds 2015 £</b>
Fundraising expenses	7,060	3,791	10,851	19,092

In 2015, of the total fundraising expense, £11,262 was to unrestricted funds and £7,830 was to restricted funds.

**7. DIRECT COSTS**

	<b>Charitable activities £</b>	<b>Total 2016 £</b>	<b>Total 2015 £</b>
Conference	26,282	26,282	22,439

**8. ANALYSIS OF GRANTS**

	<b>Grants to Institutions 2016 £</b>	<b>Grants to Individuals 2016 £</b>	<b>Total 2016 £</b>	<b>Total 2015 £</b>
Grants, Charitable activities	5,000	250	5,250	-

In 2016 1 grant was made to an institution (2015: NIL) and 1 to an individual (2015: NIL).

Grants to institutions were as follows:

	<b>2016 £</b>	<b>2015 £</b>
University College London	5,000	-



**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2016**

**9. SUPPORT COSTS**

	Charitable activities £	Total 2016 £	Total 2015 £
Rent	4,200	4,200	4,180
Office costs	7,145	7,145	1,011
Online services	3,396	3,396	871
Website and computer costs	761	761	166
Sundry expenses	445	445	415
Insurance	447	447	480
Printing, postage and stationery	2,959	2,959	4,896
Travel and accommodation expenses	6,859	6,859	2,924
Advertising	-	-	10
Depreciation - office equipment	241	241	270
GSD film documentary	-	-	4,200
Euromac expenses	8,468	8,468	10,559
Accountancy & payroll	1,388	1,388	1,397
Independent examiners fee	2,800	2,800	2,682
Wages and salaries	33,600	33,600	36,154
National insurance	1,517	1,517	1,581
	<b>74,226</b>	<b>74,226</b>	<b>71,796</b>

During the year ended 31 March 2016, the company incurred the following Governance costs:

£4,188 (2015 - £4,079) included within the table above in respect of Charitable activities.

In 2015, the company incurred the following Support costs:

£67,717 in respect of Charitable activities.

**10. ANALYSIS OF RESOURCES EXPENDED BY EXPENDITURE TYPE**

	Staff costs 2016 £	Other costs 2016 £	Total 2016 £	Total 2015 £
Expenditure on raising voluntary income	-	10,851	10,851	19,092
<b>Costs of generating funds</b>	-	10,851	10,851	19,092
Charitable activities	35,117	70,641	105,758	94,235
	<b>35,117</b>	<b>81,492</b>	<b>116,609</b>	<b>113,327</b>

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2016**

**11. NET INCOMING RESOURCES/(RESOURCES EXPENDED)**

This is stated after charging:

	2016 £	2015 £
Depreciation of tangible fixed assets: - owned by the charity	241	270

Trustees received remuneration amounting to £NIL in the current year (2015 - £NIL).

During the year, no Trustees received any benefits in kind (2015 - £NIL).

No Trustees received reimbursement of travel and subsistence expenses amounting to £NIL in the current year, (2015 - 2 Trustees - £3,330).

**12. STAFF COSTS**

Staff costs were as follows:

	2016 £	2015 £
Wages and salaries	33,600	36,154
Social security costs	1,517	1,581
	35,117	37,735

The average number of persons employed by the company during the year was as follows:

	2016 No.	2015 No.
	1	1

No employee received remuneration amounting to more than £60,000 in either year.

The key management personnel of the charity are the Trustees and Development Director. Total employee benefits of key management personnel charity were £33,600 (2015: £36,154).

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2016**

**13. TANGIBLE FIXED ASSETS**

	Office equipment £
<b>Cost</b>	
At 1 April 2015	2,876
Additions	153
At 31 March 2016	<u>3,029</u>
<b>Depreciation</b>	
At 1 April 2015	2,067
Charge for the year	241
At 31 March 2016	<u>2,308</u>
<b>Net book value</b>	
At 31 March 2016	<u>721</u>
At 31 March 2015	<u>809</u>

**14. DEBTORS**

	2016 £	2015 £
Trade debtors	3,710	4,300
Prepayments and accrued income	12,991	1,212
	<u>16,701</u>	<u>5,512</u>

**15. CREDITORS: Amounts falling due within one year**

	2016 £	2015 £
Other taxation and social security	18	-
Other creditors	4,456	5,000
Accruals and deferred income	2,957	2,215
	<u>7,431</u>	<u>7,215</u>

---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
**(A company limited by guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2016**

---

**16. FINANCIAL INSTRUMENTS**

	<b>2016</b>	<b>2015</b>
	<b>£</b>	<b>£</b>
Financial assets measured at amortised cost	<b>96,910</b>	<b>82,953</b>
Financial liabilities measured at amortised cost	<b>6,805</b>	<b>7,215</b>

Financial assets measured at amortised cost comprise cash at bank, trade debtors and accrued income.

Financial liabilities measured at amortised cost comprise accruals and other creditors

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2016**

**17. STATEMENT OF FUNDS**

	Brought Forward £	Income £	Expenditure £	Carried Forward £
<b>Unrestricted funds</b>				
General Funds	1,699	41,859	(30,792)	12,766
<b>Restricted funds</b>				
Type 2 Pompe's	18,534	10,834	(12,043)	17,325
Type 5 McArdles	24,937	6,992	(13,865)	18,064
Type 3 Cori	7,322	231	-	7,553
Type 1 Von Gierke	4,809	-	-	4,809
Euromac	3,254	14,758	(18,012)	-
Awards for All	22	-	-	22
Type 6 Hers Fund	602	-	-	602
Hardship fund	3,792	-	(250)	3,542
Conference	10,680	27,505	(38,171)	14
Medical Advisory Board	2,108	-	(2,043)	65
Specialist Care Advisor	-	35,000	(1,433)	33,567
	<u>76,060</u>	<u>95,320</u>	<u>(85,817)</u>	<u>85,563</u>
Total of funds	<u>77,759</u>	<u>137,179</u>	<u>(116,609)</u>	<u>98,329</u>

**SUMMARY OF FUNDS**

	Brought Forward £	Income £	Expenditure £	Carried Forward £
General funds	1,699	41,859	(30,792)	12,766
Restricted funds	76,060	95,320	(85,817)	85,563
	<u>77,759</u>	<u>137,179</u>	<u>(116,609)</u>	<u>98,329</u>

---

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2016**

---

**17. STATEMENT OF FUNDS (continued)**

**Restricted Funds**

**Type 2 Pompe's**

Supporting GSD Type 2, Pompe.

**Type 5 McArdles**

Supporting GSD Type 5, McArdle.

**Type 3 Cori**

Supporting GDS Type 3, Cori.

**Type 1 Von Gierke**

Supporting GSD Type 1, Von Gierke.

**Euromac**

EC DG Sanco (ref. 2012 12 14) via Euromac - contract to disseminate Euromac information throughout Europe.

**Awards for All**

The Big Lottery - production of literature on all GSD's.

**Type 6 Hers Fund**

Supporting GSD Type 6, Hers.

**Hardship Fund**

Supporting patients and families suffering hardship.

**Conference**

Supporting AGSD-UK Annual conference.

**Medical Advisory Board**

Supporting meetings of AGSD-UK Medical Advisors.

**Specialist Care Advisor**

Supporting the provision of a Pompe patient support worker.

**ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2016**

**18. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

	Restricted funds 2016 £	Unrestricted funds 2016 £	Total funds 2016 £	Total funds 2015 £
Tangible fixed assets	-	721	721	809
Current assets	85,563	19,476	105,039	84,165
Creditors due within one year	-	(7,431)	(7,431)	(7,215)
	<u>85,563</u>	<u>12,766</u>	<u>98,329</u>	<u>77,759</u>

**19. OPERATING LEASE COMMITMENTS**

At 31 March 2016 the total of the Charity's future minimum lease payments under non-cancellable operating leases was:

	Land and buildings 2016 £	2015 £
<b>Amounts payable:</b>		
Within 1 year	<u>4,200</u>	<u>4,200</u>

**20. RELATED PARTY TRANSACTIONS**

There were no related party transactions for the year ended 31 March 2016.

**21. FIRST TIME ADOPTION OF FRS 102**

It is the first year that the company has presented its financial statements under SORP 2015 and FRS 102. The following disclosures are required in the year of transition. The last financial statements prepared under previous UK GAAP were for the year ended 31 March 2015 and the date of transition to FRS 102 and SORP 2015 was therefore 1 April 2014. As a consequence of adopting FRS 102 and SORP 2015, a number of accounting policies have changed to comply with those standards.

The policies applied under the company's previous accounting framework are not materially different to FRS 102 and have not impacted on funds or net income/expenditure.